Episode 8 brings the series together with a pragmatic launch integration plan: how a specialty biologic turns strategy into day-one execution. We outline the success factors that consistently separate winners: clear, payer-oriented messaging; layered evidence with early RWE; real-time competitive response; cross-TA access innovation; and tight alignment across Access, HEOR, Medical, and Field.

Episode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch.

Episode 6 pulls back the curtain on competitive intelligence (CI) maturity in severe asthma launches—what top teams track, how fast they learn, and why it matters for pricing, access, messaging, and patient support. We contrast integrated, always-on CI programs with reactive, vendor-only approaches, and show how social listening, field feedback loops, KOL digital patterns, and payer advisory monitoring translate into real decisions.

Episode 5 examines how real-world evidence (RWE) is now the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations.

In Episode 4 we'll explore how existing brands in the Severe Asthma market are positioning their value stories to payers — in both economic and clinical terms. The episode will examine the structure, tone, and content of competitor access messaging, including AMCP dossiers, value decks, and in-field conversations. Lumara’s team must develop a differentiated and credible payer narrative — one that can cut through entrenched positioning and resonate with pharmacy and medical directors.

Episode 3 zeroes in on the first-fill moment and early adherence—where HUB design, copay policy, and specialty-pharmacy handoffs can make or break momentum. We unpack the essentials of high-performing programs (benefits investigation, real-time PA tracking, FRM support, nurse case management, and digital enrollment) and spotlight where patients and offices most often stall.

Episode 2 dives into the real engine of access: how plans decide who gets preferred, who gets blocked, and what it really costs to move tiers.

In Episode 1, we introduce Lumara—a fictional, once-monthly biologic with dual IL-5 and IL-13 inhibition—poised to enter a crowded severe-asthma market.

Series Overview: The Lumara Series is an 8-episode, TA-specific competitive intelligence podcast produced by Genflare using commercially...

The seamless, AI-powered experiences consumers encounter in travel, retail, and entertainment shape their expectations of what healthcare support should feel like.

Turning Up the Volume: How AI Voice Technology Reshaped Publishing—and What It Means for Other Industries Artificial intelligence is now...

Patients facing cancer, autoimmune disease, or rare disorders don’t have time to spare—but too often, the very first step in their...

What if your most consistent team member never got tired, forgot nothing, escalated wisely, and worked 24/7 without complaint?